

**NOTRE DAME INTERMÉDICA PARTICIPAÇÕES S.A.**

Corporate ID No. 19.853.511/0001-84

Publicly-held Company

**MATERIAL FACT**

Notre Dame Intermédica Participações S.A. (“**GNDI**”), pursuant to the provisions of article 157, paragraph 4, of Law No. 6,404/76 of CVM Resolution No. 44/21, hereby announces to its shareholders and to the Market in general that, on February 10, 2022, Notre Dame Intermédica Saúde S.A and Gralha Azul Administração e Participação Ltda., wholly-owned subsidiaries of GNDI, entered into a purchase and sale agreement to acquire HSCOR – Hospital do Coração de Duque de Caxias Ltda. (“**HSCOR** or “**Company**”) (“**Transaction**”).

GNDI now indirectly owns 100% (hundred percent) of the shares of HSCOR and the Real Estate where the hospital is located. The purchase price was paid in cash, deducting the net debt and a portion retained for contingencies.

HSCOR was founded in 2007 in the city of Duque de Caxias, metropolitan region of Rio de Janeiro. The Company currently operates a high-complexity cardiology hospital, recently renovated and with ONA accreditation, clinical analysis laboratory and an imaging park – including tomography and hemodynamics. It has 70 beds, of which 20 are ICU beds, a modern surgical center with 6 rooms, 2 of which are hybrid rooms for high-complexity vascular and neurological procedures.

In 2021, HSCOR presented net sales of R\$ 50.6 million. The acquisition price (“Enterprise Value”) was R\$83 million. The integration plan foresees operational and administrative synergies with GNDI’s operations in the state of Rio de Janeiro, which with this acquisition has five hospitals, ten clinical centers, two stand-alone emergency rooms, in addition to two new emergency rooms under construction at the center of Rio de Janeiro and in Nova Iguaçu.

The closing of the Transaction is not subject to prior approval by the Brazilian Agency of Supplemental Health (Agência Nacional de Saúde Suplementar - ANS) nor the Brazilian Administrative Council for Economic Defense (Conselho Administrativo de Defesa Econômica - CADE).

With the Transaction announcement, the Company demonstrates the intention to maintain its growth strategy in the State of Rio de Janeiro, continually investing in the expansion and strengthening of its owned network, reinforcing its commitment to create value for its shareholders, customers and society.

The Company clarifies that the Transaction is not subject to and, therefore, will not be submitted to shareholders’ approval provided for in Article 256 of Law No. 6,404/76, nor will entail, pursuant to the guidance provided in the Official Letter/CVM/SEP/No. 01/2021, the withdrawal right to the Company’s shareholders, considering that the acquisition was performed by Notre Dame Intermédica Saúde S.A and Gralha Azul Administração e Participação Ltda., wholly-owned subsidiaries of GNDI.

São Paulo, February 10, 2022.

**Glauco Desiderio**

Investor Relations Officer